Molecular Formula | C23H21N5O3S |
Molar Mass | 447.51 |
Density | 1.34±0.1 g/cm3(Predicted) |
Solubility | DMSO: ≥ 58 mg/mL |
pKa | 12.60±0.70(Predicted) |
Storage Condition | -20℃ |
In vitro study | In HeLa cells, 4SC-202 induced hyperacetylation of histone H3 with an EC50 of 1.1 μm. 4SC-202 induces G2/M cell cycle arrest by interfering with the normal development of the mitotic spindle and causes spindle collapse and multiple nucleation centers. In addition, 4SC-202 exhibited broad-spectrum anti-tumor activity against human cancer cell lines with an IC50 of 0.7 μm. |
In vivo study | In Vivo, 4SC-202 has high oral bioavailability and exhibits high metabolic stability and low plasma clearance. In the A549 NSCLC xenograft and RKO27 colon cancer models, 4SC-202 (120 mg/kg p.o.) showed significant potent antitumor activity. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.235 ml | 11.173 ml | 22.346 ml |
5 mM | 0.447 ml | 2.235 ml | 4.469 ml |
10 mM | 0.223 ml | 1.117 ml | 2.235 ml |
5 mM | 0.045 ml | 0.223 ml | 0.447 ml |